Researchers in Beijing reported phase 2 trial results on a combination approach for primary immune thrombocytopenia (ITP), a condition in which achieving a lasting treatment response can be especially difficult. The study evaluated low-dose baricitinib together with danazol in patients with difficult-to-treat disease.
According to the report, the randomized, controlled trial suggests that this low-dose baricitinib plus danazol regimen may help improve outcomes for people with primary ITP who have been hard to manage with existing options. The authors highlighted the ongoing need for therapies that can deliver a more sustained response in this patient group.
The study was led by investigators at the Peking University Institute of Hematology and Peking University People’s Hospital in Beijing, China. While the trimmed report does not provide full efficacy details here, the published summary indicates the combination showed potential activity with an acceptable safety profile.
These findings position baricitinib plus danazol as a treatment strategy worth watching in primary ITP. The phase 2 results add early clinical support for further study of the regimen in patients with difficult-to-treat disease.
